<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:DXCM (USA) Also Trade In: Germany Mexico

DexCom Inc $ 150.89 -5.73 (-3.66%)

On watch
Volume:
437,407
Avg Vol (1m):
843,353
Market Cap $:
13.76 Bil
Enterprise Value $:
13.48 Bil
P/E (TTM):
0.00
P/B:
19.73
Warning! GuruFocus has detected 1 Severe warning sign with DXCM. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)

DXCM News and Headlines - DexCom

GuruFocus Articles Total 34
  • 1
  • 2

Investment company Peregrine Capital Management Llc (Current Portfolio) buys Atkore International Group Inc, Omnicell Inc, Verra Mobility Corp, IAA Inc, DexCom Inc, sells Genesee & Wyoming Inc, Copart Inc, Array BioPharma Inc, New Relic Inc, MGP Ingredients Inc during the 3-months ended 2019Q3, according to the most recent filings of the investment company, Peregrine Capital Management Llc. As of 2019Q3, Peregrine Capital Management Llc owns 290 stocks with a total value of $3.7 billion. These are the details of the buys and sells.
0 Views    [email protected]    2019-10-16 15:38
Investment company Silverleafe Capital Partners, LLC (Current Portfolio) buys DexCom Inc, ishares Gold Trust, The Walt Disney Co, Anthem Inc, Dollar Tree Inc, sells SPDR S&P 500 ETF Trust, Vanguard Value ETF, Facebook Inc, iShares North American Tech-Software ETF, Pfizer Inc during the 3-months ended 2019Q3, according to the most recent filings of the investment company, Silverleafe Capital Partners, LLC. As of 2019Q3, Silverleafe Capital Partners, LLC owns 64 stocks with a total value of $143 million. These are the details of the buys and sells.
0 Views    [email protected]    2019-10-04 17:38

President, CEO and Chairman of Dexcom Inc (30-Year Financial, Insider Trades) Kevin R Sayer (insider trades) sold 10,000 shares of DXCM on 10/01/2019 at an average price of $149.6 a share. The total sale was $1.5 million.

DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. DexCom Inc has a market cap of $14.35 billion; its shares were traded at around $157.41 with and P/S ratio of 11.58. DexCom Inc had

0 Views    [email protected]    2019-10-03 23:15

PR Newswire

NEW YORK, March 21, 2019 /PRNewswire/ -- Report entitled "Sugar High" outlines how DXCM may face 45%-60% intermediate downside risk to approximately $65 to $85 per share due to the market's significant misunderstanding of the true addressable market of Dexcom's G6 continuous glucose monitor (CGM), Abbot's current dominance even before the launch of the functionally equivalent Libre 2 and the impending growth wall Dexcom will hit in 2020 as a result

0 Views    PRNewswire    2019-03-21 20:01

NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Infinera Corporation (INFN), Alliant Energy Corporation (LNT), Galectin Therapeutics Inc. (GALT), DexCom, Inc. (DXCM), Cutera, Inc. (CUTR), and Care.com, Inc. (:CRCM), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

0 Views    Marketwired    2019-02-26 13:02

NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DexCom, Inc. (DXCM), MiX Telematics Limited (:MIXT), Resolute Forest Products Inc. (:RFP), Equinix, Inc. (EQIX), Johnson & Johnson (:JNJ), and Vedanta Limited (:VEDL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

DXCM DOWNLOAD:

0 Views    Marketwired    2018-10-22 12:04

NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Humana Inc. (:HUM), DexCom, Inc. (DXCM), Royal Dutch Shell PLC (:RDS-A), First Connecticut Bancorp, Inc. (FBNK), Bank of America Corporation (:BAC), and Equifax, Inc. (:EFX), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

0 Views    Marketwired    2018-06-14 12:01

PR Newswire

SALEM, N.H. and WILSONVILLE, Ore., June 5, 2018 /PRNewswire/ -- AgaMatrix, Inc., a developer of diagnostic technologies for glucose monitoring and wholly owned subsidiary of AgaMatrix Holdings LLC, announced a prevailing outcome in a retaliatory patent infringement lawsuit brought by Dexcom, Inc. (NASDAQ: DXCM).

AgaMatrix, Inc. | 2017 (PRNewsfoto/AgaMatrix)

In a decision ruled earlier this year by the US District

0 Views    PRNewswire    2018-06-05 16:20
Amgen, DexCom among those companies

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.

Seven gurus are invested in Amgen Inc. (AMGN).

The company discovers, develops and commercializes therapies to treat cancer. It has a market cap of $117.02 billion. Its revenue has grown 10.40% annually over the past 10 years.

The stock is trading with a price-earnings (P/E) ratio of 66.08. The current price of $172.93 is 12.98% below its 52-week high and 15.08% above its 52-week low. Over the past 10 years, it has returned a gain of 311%.

The company’s largest shareholder among the

69 Views    Tiziano Frateschi    2018-04-23 14:38

NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DexCom, Inc. (DXCM), Equinix, Inc. (EQIX), Fitbit, Inc. (:FIT), Gilead Sciences, Inc. (GILD), Humana Inc. (:HUM), and Microsoft Corporation (MSFT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

DXCM DOWNLOAD:

0 Views    Marketwired    2018-04-17 12:03
The fund favored two industries within the sector

The Vanguard Health Care Fund (Trades, Portfolio), managed my Jean Hynes, bought six new positions in the third quarter, it revealed Monday.

The new positions represented two industries equally: biotech, and medical diagnostics and research. The three from biotech were: bluebeard bio Inc. (BLUE), BeiGene Ltd. (BGNE) and Galapagos NV (XAMS:GLPG). Medical instruments and diagnostics companies were: Essilor International SA (XPAR:EI), DexCom Inc. (DXCM) and PRA Health Sciences Inc. (PRAH).

The portfolio of the Vanguard Health Care Fund (Trades, Portfolio) had 80 positions as of the end of the third quarter. Together, they had

965 Views    Holly LaFon    2017-10-30 21:45
The company has a disruptive product in the diabetes monitoring industry that could be vastly profitable

(This article was originally featured on CNA Finance)

Disclosure: I hold no position in any stock mentioned herein and have no plans to open any position within the next 72 hours.

201 Views    Joshua Rodriguez    2017-06-07 20:09
Stocks with negative 6-month performances

While gurus hold positions in these companies, the stock price and returns continue to fall. These are the worst-performing stocks over the last three months with a long-term presence in more than four gurus’ portfolios.

Acuity Brands Inc. (AYI) had a negative performance of 25.9% over the last six months. Three mutual funds hold the stock with a total weight of 0.06% on their portfolios.

The company has a market cap of $7.83 billion, and the stock is trading with a price-sales (P/S) ratio of 2.27. The price of $177.68 is 36.74% below its 52-week high and 4.81% above

178 Views    Tiziano Frateschi    2017-04-14 21:08
Insiders sell holdings in Fidelity National Financial, DexCom and Facebook

According to GuruFocus Insider Data, the recent CFO sells were: Fidelity National Financial Inc. (FNF), DexCom Inc. (DXCM) and Facebook Inc. (FB).

Fidelity National Financial: EVP and CFO Anthony Park sold 34,542 shares

EVP and CFO Anthony Park sold 34,542 shares at a price of $35.66 on June 9. The price of the stock has decreased by 2.78%. Fidelity National Financial has a market cap of $11.88 billion, and its shares were traded around $34.67. The company has a P/E ratio of 18.44 and P/S ratio of 1.08. The trailing 12-month dividend yield and forward dividend yield of Fidelity National

2576 Views    Myra Ramdenbourg    2016-06-28 19:23
Guru stock highlight

Another health care holding, DexCom, Inc., (NASDAQ:DXCM) sells a continuous glucose monitoring system for diabetics. Although this is an unusual investment for the portfolio because of its extended trading multiple, we think DexCom’s fundamentals justify our investment. Over the last three years, DexCom has launched a series of new products driving a dramatic acceleration in revenue growth. We believe the company’s new product pipeline remains robust and will lead to further adoption among the growing population of diabetics.

From the Baron Funds Small Cap Fund winter newsletter 2016.

490 Views    Holly LaFon    2016-01-14 17:04
By Baron Small Cap Fund Portfolio Manager Cliff Greenberg

Compared to large-cap stocks, the landscape of small-cap stocks is broader, less well-known, and more volatile. While these aspects of the small-cap space may cause some investors to steer clear, it has its distinct advantages. Historically, small caps have outperformed large caps while providing investors with diversification. We also believe that, given current market conditions, now may be an opportune time in which to invest in small cap stocks. This equity asset class tends to outperform large caps in a rising interest rate environment. In addition, small-caps are typically less exposed to foreign exchange headwinds generated by a strong dollar

862 Views    Holly LaFon    2016-01-14 16:40
DexCom, Gilead Sciences, Palo Alto Networks, Salesforce.com lead the way

According to GuruFocus Insider Data, the largest insider sells during the past week were DexCom Inc. (DXCM), Gilead Sciences Inc. (GILD), Palo Alto Networks Inc. (PANW) and Salesforce.com Inc. (CRM).

The overall trend of insiders is illustrated in the chart below:

DexCom Inc.: Executive Chairman Terrance H. Gregg sold 160,001 shares

DexCom Executive Chairman Terrance H. Gregg sold 160,001 shares during the past week at an average price of $95.73 per share.

DexCom designs, develops and commercializes glucose monitoring systems for ambulatory use by people with diabetes. The company has a market cap

663 Views    Jimmy Xiao    2015-09-15 15:31
Gilead CFO sells 6,250 shares of the company

According to GuruFocus Insider Data, the recent CFO sales were: Gilead Sciences Inc. (GILD), DexCom Inc. (DXCM), and Palo Alto Networks Inc. (PANW).

Gilead Sciences Inc.: EVP, CFO Robin L Washington sold 6,250 shares

On Sept. 2, EVP and CFO Robin L Washington sold 6,250 shares at an average price of $102.2. The price of the stock has increased by 7.27%. Gilead Sciences Inc. has a market cap of $160.89 billion and its shares were traded at around $109.63.The company has a P/E ratio of 11.49 and P/S ratio of 5.97 with a dividend yield of 0.39%. Over the past

1385 Views    Myra Ramdenbourg    2015-09-13 19:16

Stopping by my local Starbucks on Tuesday, this was on the front page of the Star-Ledger:

Don't Panic

A couple of embarrassingly Jersey items on the left, but in the middle is the typical advice offered to unhedged, long-only investors when the crap hits the fan. A better approach, I think, is for investors to be positioned in such away that they'll have no reason to panic, because their downside is strictly limited. That's the point of the hedged portfolio method.

Stocks for small hedged portfolio weather Tuesday's session

In a post

394 Views    David Pinsen    2015-08-26 16:16

DexCom, Inc. (DXCM) sells a continuous glucose monitoring device for insulin dependent diabetes. DexCom reported very strong results. Revenues grew 55% in the quarter, and the company reiterated guidance for continued exceptional growth. The company launched its “share” system, which allows parents or spouses to receive the users’ blood glucose data from the users’ handheld devices, an important new feature. And they filed for approval of their next generation offering that will transmit data directly to a smartphone, eliminating the need to carry a receiver. Strong new patient starts, more accurate and feature rich products, and an expanding addressable market

385 Views    Holly LaFon    2015-08-19 15:18

Headlines Total 288
  • 1
  • 2
  • 3

2019-10-18 $ 156.92 (0.16%)
11:53am
2019-10-15 $ 152.97 (-4.5%)
12:22pm
2019-10-09 $ 153.9 (2.32%)
9:31am
2019-10-04 $ 160.37 (1.88%)
12:38pm
2019-10-03 $ 157.41 (5.72%)
6:15pm
2019-09-27 $ 148.51 (-0.92%)
5:52pm
2019-09-25 $ 153.76 (0.2%)
10:49am
2019-09-23 $ 155.33 (0.6%)
4:03pm
2019-09-20 $ 154.4 (-0.38%)
8:56am
2019-09-15
2:00pm
2019-09-13 $ 146.26 (-0.61%)
8:13am
2019-09-03 $ 172.26 (0.38%)
7:50am
2019-08-31
7:29am
Is Dexcom a Buy? - www.fool.com
2019-08-30 $ 171.61 (-0.26%)
2:20pm
2019-08-29 $ 172.06 (-1.79%)
7:03am
2019-08-20 $ 168.28 (2.87%)
6:00am
2019-08-15 $ 158.53 (3.28%)
8:53am
2019-08-13 $ 157.3 (3.53%)
2:27pm
2019-08-12 $ 151.93 (-2.26%)
10:21am
2019-08-03
4:05pm
2019-08-02 $ 144.21 (-2.77%)
8:27am
8:15am
2019-08-01 $ 148.32 (-5.45%)
6:00am
4:01am
2019-07-31 $ 156.87 (0.31%)
10:04pm
2019-07-30 $ 156.39 (1.86%)
8:40am
2019-07-25 $ 151.49 (-0.96%)
6:37am
2019-07-24 $ 152.96 (0.66%)
9:32am
2019-07-23 $ 151.95 (-2.04%)
8:27pm
2019-07-15 $ 151.11 (1.3%)
10:00am
2019-07-12 $ 149.17 (-2.18%)
12:06pm
2019-07-11 $ 152.5 (1.07%)
8:00am
2019-07-09 $ 147.78 (1.48%)
11:22am
2019-07-05 $ 146.99 (2.53%)
8:25am
2019-07-03 $ 143.36 (-1.59%)
7:00am
2019-06-28 $ 149.84 (2.75%)
10:29am
2019-06-17 $ 150.34 (1.55%)
9:36am
9:22am
2019-06-14 $ 148.04 (1.18%)
12:27pm
7:43am
2019-06-10 $ 138.44 (9.89%)
4:45pm
2019-06-07 $ 125.98 (4.37%)
7:26am
2019-06-06 $ 120.7 (-2.24%)
8:25am
2019-06-02
12:17pm
2019-05-31 $ 121.3 (1.17%)
8:31am
2019-05-15 $ 121.49 (1.03%)
1:21pm
2019-05-07 $ 119.61 (-2.13%)
8:26pm
2019-05-02 $ 120.37 (1.48%)
6:24pm
8:51am
2:29am
2019-05-01 $ 118.62 (-2.02%)
4:25pm
2019-04-29 $ 124.43 (0.21%)
8:01am
2019-04-25 $ 118.12 (-0.59%)
8:58pm
2:29pm
2019-04-24 $ 118.82 (0.67%)
9:33am
2019-04-23 $ 118.03 (1.22%)
9:58am
2019-04-17 $ 111.38 (-5.42%)
10:54am
2019-04-13
7:30pm
2019-04-12 $ 117.88 (-1.19%)
8:33am
2019-04-11 $ 119.3 (0.35%)
4:45pm
12:23pm
2019-04-05 $ 116.92 (-0.2%)
4:45pm
2019-04-04 $ 117.16 (-0.45%)
6:21pm
2019-04-01 $ 115.17 (-3.3%)
9:58am
9:40am
2019-03-29 $ 119.1 (0.61%)
8:42am
8:40am
2019-03-27 $ 115.54 (-4.47%)
7:34am
2019-03-26 $ 120.95 (-2.52%)
11:00am
10:48am
2019-03-25 $ 124.08 (-3.84%)
7:15pm
9:53am
9:49am
2019-03-23
8:30am
2019-03-22 $ 129.03 (-9.24%)
3:54pm
3:19pm
2:34pm
9:33am
9:11am
5:01am
2019-03-21 $ 142.16 (-2.74%)
3:28pm
2019-03-20 $ 146.16 (-0.53%)
8:30am
2019-03-19 $ 146.94 (0.54%)
9:30am
2019-03-18 $ 146.15 (-3.21%)
12:43pm
8:08am
2019-03-16
12:00pm
2019-03-13 $ 147.46 (2.55%)
7:12pm
2019-03-12 $ 143.79 (-0.21%)
7:48am
6:00am
2019-03-11 $ 144.09 (0.59%)
8:19am
7:48am
2019-03-08 $ 143.24 (0.12%)
10:46am
Is DexCom a Buy? -- - www.fool.com
7:52am
2019-03-07 $ 143.07 (-0.24%)
7:47am
7:38am
2019-03-06 $ 143.41 (-2.42%)
7:57am
2019-03-05 $ 146.97 (3.87%)
6:46am
6:42am
2019-03-04 $ 141.5 (-1.39%)
7:31am
2019-03-01 $ 143.49 (2.99%)
7:28pm
Total 288
  • 1
  • 2
  • 3